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Abstract; 
Background; Hypertensive disorders such as eclampsia is significant contributor to maternal and perinatal 
mortality and morbidity worldwide particularly in the developing countries. This study was done to determine 
the frequency of recurrent seizures in patients seeking loading dose of MgSO4 only in eclampsia. Materials & 
Method: Pregnant ladies (n = 114) of any parity, 15-35 years old having more than 20 weeks gestational 
amenorrhea from last menstrual period were included in our study. Patients admitted with eclampsia were 
examined for recurrent seizures. Frequency of recurrent seizures with loading dose of mgso4 was noted till 48 
hours of receiving loading dose of MgSO4. However if there was a repeat fit with loading dose of MgSO4 then 
an additional 2 gms MgSO4 was given intravenously and shifted to maintenance regimen. Results; Mean age of 
our study cases was noted to be 29.75 ± 4.56 years (with minimum age of our patients was 22 years while 
maximum age was 35 years). Mean parity of our study cases was noted to be 2.03 ± 1.31. Majority of our study 
cases i.e. 64 (56.1%) had parity less than 3 and gravidity less than 4 was noted in 82 (71.9%) of our study cases. 
Mean gestational age of our study cases was noted to be 30.80 ± 4.90 weeks (with minimum gestational age was 
22 weeks and maximum gestational age was 38 weeks). Mean body mass index (BMI) of our study cases was 
noted to be 24.67 ± 3.02 kg/m
2 
and obesity was noted in 25 (21.9%) of our study cases. Mean number of seizures 
(before start of therapy) was 6.46 ± 3.21 (with minimum no. of seizures was 3 while maximum no. of seizures 
were noted to be 15). Recurrence of seizures was noted in 11 (9.6%) of our study cases. Conclusion; Our study 
results have shown that recurrence of seizures was quite low with loading dose of magnesium sulphate. It is safe, 
effective and reliable therapy in controlling seizures in eclampsia. Provision of loading dose of MgSO4 to these 
patients will not only reduce painful intramuscular injections but also helpful to reduce related costs. So use of 
loading dose of MgSO4 regimen is recommended of our group of patients as most of our patients are poor. 
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Introduction: 
Over a half million women die each year from pregnancy related causes and 99% of these deaths occur 
in middle and low income countries.1 Eclampsia is a common cause of maternal mortality world wide 
particularly in developing countries.2 Eclampsia accounts for more than 50,000 maternal deaths each year.3 
Eclampsia is a life threatening multisystem disorder with complex pathogenesis.
4,5
 Among the many 
anticonvulsants MgSO4 is the drug of choice for prevention of recurrence of seizures in eclampsia.
6
 It acts on 
smooth muscles causing relaxation and vasodilation, increasing cerebral perfusion and also inhibit NMDA 
receptors thereby increasing seizure threshold.7 MgSO4 also decrease cerebral edema formation after brain 
injury.
8
 MgSO4 can be given by Zuspan regimen (loading dose of 4gms I/V and maintenance dose of 1gms/hour 
I/V for 24 hours) or Pritchard regimen (loading dose of 4gms I/V and 10gms I/M and maintenance dose of 5gms 
I/M every 4 hour for 24 hours.9 In Dhaka Medical College, according to the guidelines published by eclampsia 
working group the dose schedule is 4gms I/V and 3gms I/M in each buttock as loading dose followed by 2.5gms 
I/M every 4 hours in alternate buttock till 24 hours.
10
 A potential concern for MgSO4 therapy is the risk of side 
effects like renal impairment, respiratory and cardiac arrest and CNS depression which requires careful 
monitoring of urine output respiratory rate, heart rate and tendon reflexes. Complications increases with duration 
of treatment.11 Similarly cost of therapy would inevitably increase with duration of treatment. It has been 
recently suggested that an initial loading dose of MgSO4 is sufficient to arrest convulsions and we also observed 
that most of the patients did not receive maintenance dose due to suspicion of toxicity and they did not convulse 
any further.12-15            A study was conducted at Maternity Unit, Specialist Hospital, Sokoto Nigeria.13 It showed 
that loading dose of MgSO4 was effective in 92% of eclamptic patients.
13  Recurrent seizures were observed in 
8% of patients which is comparable to the ones who have received standard treatment.
13
 A study conducted at 
Dhaka Medical College & Hospital Bangladesh showed that the recurrent convulsion rate was almost the same 
(3.96% versus 3.52%) between the groups that had only a loading dose of 10gms (4gms  I/V + 6gms I/M) and 
the control group that had both the loading dose and maintenance dose of 2.5gms 4 hourly for 24 hours.10  
 
Materials & Method: 
Pregnant ladies (n = 114) of any parity, 15-35 years old having more than 20 weeks gestational amenorrhea from 
last menstrual period were included in our study. Other causes of convulsions like epilepsy,  meningitis (history 
of fever, unconsciousness and neck rigidity) and metabolic disorders like hypoglycemia (low blood glucose level 
< 60mg/dl), hypocalcemia (low calcium level in the blood < 8.5mg/dl), hyponatremia (low sodium level in the 
blood < 130mEq/L) were excluded from our study.  
Eclamptic patients fulfilling the inclusion and exclusion criteria admitted in the labour room of Nishtar Hospital 
Multan, Pakistan were included in the study. Patients admitted with eclampsia were examined for recurrent 
seizures. Frequency of recurrent seizures with loading dose of mgso4 was noted till 48 hours of receiving loading 
dose of MgSO4. However if there was a repeat fit with loading dose of MgSO4 then an additional 2 gms MgSO4 
was given intravenously and shifted to maintenance regimen. 
 
Results;  
Our study included a total of 114 pregnant women presenting with eclampsia who met inclusion criteria of our 
study. Mean age of our study cases was noted to be 29.75 ± 4.56 years (with minimum age of our patients was 
22 years while maximum age was 35 years). Our study results have indicated that majority of our study cases i.e. 
76 (66.7%) were from age group of 26 – 35 years of age. Mean parity of our study cases was noted to be 2.03 ± 
1.31. Majority of our study cases i.e. 64 (56.1%) had parity less than 3 and gravidity less than 4 was noted in 82 
(71.9%) of our study cases. Mean gestational age of our study cases was noted to be 30.80 ± 4.90 weeks (with 
minimum gestational age was 22 weeks and maximum gestational age was 38 weeks). Majority of our study 
cases i.e. 77 (67.5%) had gestational age more than 30 weeks. Mean body mass index (BMI) of our study cases 
was noted to be 24.67 ± 3.02 kg/m2 and obesity was noted in 25 (21.9%) of our study cases. Mean number of 
seizures (before start of therapy) was 6.46 ± 3.21 (with minimum no. of seizures was 3 while maximum no. of 
seizures were noted to be 15) and majority of these patients i.e. 62 (54.4%) had history of 1 – 5 seizures. 
Recurrence of seizures was noted in 11 (9.6%) of our study cases. 
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Discussion; 
Magnesium sulfate (MgSO4) has been used throughout the 20
th
 century for prevention of eclamptic seizures and 
continues to be used extensively 16-18. Our study included a total of 114 pregnant women presenting with 
eclampsia who met inclusion criteria of our study. Mean age of our study cases was noted to be 29.75 ± 4.56 
years (with minimum age of our patients was 22 years while maximum age was 35 years). Our study results have 
indicated that majority of our study cases i.e. 76 (66.7%) were from age group of 26 – 35 years of age. Sharafat 
et al 1  also reported 28 years mean age which is similar to that of our study results. A study conducted by Shoaib 
et al 
2 
 reported 28.06 ± 5.5 years mean age of these patients, these results are in compliance with that of our 
study results. Aziz et al 
19
 also reported that majority of eclamptic patients belonged to age groups of 21-29 years 
which is similar to our study results. Abdullah et al 
20
 reported 28 years mean age of the pregnant ladies having 
eclampsia, these findings are in compliance with that of our study results. Rathore et al from Lahore 21 also 
reported similar age range.  Regmi et al 12 reported 21 ± 3 years mean of eclamptic women which is a bit less 
than that reported in our study.  
Mean parity of our study cases was noted to be 2.03 ± 1.31. Majority of our study cases i.e. 64 (56.1%) had 
parity less than 3 and gravidity less than 4 was noted in 82 (71.9%) of our study cases. Most of them were 
primigravidas, similar results have been reported by Aziz et al 19 and Abdullah et al 20 that eclampsia being more 
common in primigravida. Regmi et al 
12 
also reported primigravida predomination which is in compliance with 
that of our study results. Shoaib et al 
2 
also reported mean parity was 2.46 ± 1.54. These results are similar to that 
of our study results. Similar results have been reported by Sharafat et al 
1
. 
Mean gestational age of our study cases was noted to be 30.80 ± 4.90 weeks (with minimum gestational age was 
22 weeks and maximum gestational age was 38 weeks). Majority of our study cases i.e. 77 (67.5%) had 
gestational age more than 30 weeks. Aziz et al 
19
 has reported similar results. Shoaib et al 
2 
reported mean 
gestational age to be 34.43±2.50 weeks which similar to our study results. Mean body mass index (BMI) of our 
study cases was noted to be 24.67 ± 3.02 kg/m
2 
and obesity was noted in 25 (21.9%) of our study cases. Mean 
number of seizures (before start of therapy) was 6.46 ± 3.21 (with minimum no. of seizures was 3 while 
maximum no. of seizures were noted to be 15) and majority of these patients i.e. 62 (54.4%) had history of 1 – 5 
seizures. Regmi et al 12 5.93 ± 4.76 mean no. of seizures, these results are in compliance with that of our study 
results.  
Recurrence of seizures was noted in 11 (9.6%) of our study cases. A study conducted by Aziz et al 
19
 from 
Hyderabad reported 7 % recurrence of seizures. These findings are similar to that of our study results.  Regmi et 
al 12 reported recurrence of seizures in 5 % (2/40) eclamptic patients treated with loading dose of MgSO4. These 
findings are in compliance with that of our study results. Shoaib et al 
2 
also reported loading dose recurrence was 
only 2 % which shows compliance with our study results. Sharafat et al 
1 
reported 100 % control of seizures and 
there were no recurrence. Recurrent seizures were observed in 8% of patients which is comparable to the ones 
who have received standard treatment as reported by Ekele et al.
13 
 
Conclusion; 
Our study results have shown that recurrence of seizures was quite low with loading dose of magnesium 
sulphate. It is safe, effective and reliable therapy in controlling seizures in eclampsia. Provision of loading dose 
of MgSO4 to these patients will not only reduce painful intramuscular injections but also helpful to reduce related 
costs. So use of loading dose of MgSO4 regimen is recommended of our group of patients as most of our patients 
are poor. 
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